Why the study?
Does chronic antiplatelet therapy improve mortality or alter host response in patients admitted with sepsis?
Population
972 patients admitted with sepsis to mixed intensive care units (ICUs)
Comparison
Chronic antiplatelet therapy before admission vs No chronic antiplatelet therapy
Design
Cohort
Follow-up
up to 90 days
Authors
Loading...
Does not support antiplatelet use to reduce sepsis mortality; leaves open need for RCTs on host response.
Does chronic antiplatelet therapy improve mortality or alter host response in patients admitted with sepsis?
Pre-existing chronic antiplatelet therapy does not alter the clinical presentation, host response biomarkers, or 90-day mortality in patients admitted to the ICU with sepsis.
Wiewel et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: